The international surgical journal with global reach

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.

Published: 15th August 2012

Authors: Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al. et al.

Conclusion

In this study that included 331 patients, progression-free survival was improved in patients on vandetanib: hazard ratio 0.46, 95 per cent confidence interval 0.31 to 0.69, P<0.001.

Pubmed Link